Bioclinical parameters driving decision-making of subsequent lines of treatment in metastatic castration-resistant prostate cancer.

Metastatic Sites All phase 2 or 3 clinical trials showed a significant trend over time ( P = 0.001) of increasing proportions of patients with non-osseous metastasis (lymph node, visceral, and soft tissue) (1.4% per year increase), with stable proportion of liver involvement [ 22 ].

also in 9,775 other papers